Preimplantation Genetic Testing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
The preimplantation genetic testing market studied was anticipated to grow with a CAGR of 10.5% during the forecast period. The major factor attributing to the growth of the market is a rising awareness among parents regarding advancements in diagnostics with a huge volume of neonatal deaths due to complications during childbirth. The growing prevalence of congenital genetic diseases like Edwards syndrome, and common pediatric respiratory disorders such as pneumonia, and asthma are observed in recent years. As per the estimates published by the United Nations Children's Fund (UNICEF) in November 2018, about 3 million deaths occurred due to pediatric pneumonia worldwide each year. These abnormalities occur almost exclusively in couples with hereditary disorders, which was observed to occur majorly in industrialized nations. Thus, increased demand for earlier diagnosis and a rise in government initiatives to control the healthcare burden is likely to drive the pre-implantation genetic testing market.
The HLA typing by application segment is expected to account for the largest held the largest of the pre-implantation genetic testing market. Dominance can be owing to a rising volume of patients with damaged bone marrow or defective immune system. This results in an increased volume of hematopoietic stem cell transplantations (HSCT), necessitating the tests. Also, their increased application in evaluating interconnected matched donors and unrelated donors for safer HSCT is expected to drive the growth of the segment. On the other hand, inherited genetic disease testing is anticipated to witness the highest CAGR during the forecast period. The lucrative growth can be due to their ability to detect diseases in offspring and increased awareness among the public about the inheritance of these diseases by future generations. Furthermore, steep rising incidences of inherited genetic diseases, such as Marfan syndrome, cystic fibrosis, fragile X syndrome hemoglobin disorders, and others, are driving the growth of the segment.
North America is expected to dominate the pre-implantation genetic testing market. The dominance is owing to a growing volume of chromosome abnormality cases leading to various genetic disorders. Aneuploidy is the most common causing Down syndrome among newborn babies in the united states, which holds the major revenue share in the North American market. According to the World Health Organization report published in 2018, down syndrome continues to be the most common chromosomal disorder affecting 6,000 babies born in the United States each year. This, in turn, resulted in high demand for earlier diagnosis to identify the genetic defects in embryos drive the market in the region. Launch of new products by key players and a rise in improvements in healthcare infrastructure in the United States generates more revenue. Rise in government initiatives to create awareness in public and growing preference among couples for these tests during IVF and other artificial insemination procedures further stimulate the growth of the preimplantation genetic testing market in the region.
The preimplantation genetic testing market is moderately competitive and consists of several major players. Few of the key players dominating the market are following various strategies like an increased focus on R&D and the launch of new products. In October 2019, PerkinElmer launched PG-Seq Rapid Non-Invasive Pre-implantation Genetic Testing Kit for Aneuploidy (PGT-A). It is a non-invasive alternative to conventional IVF embryo biopsies, which is expected to impact the market positively. Some of the major companies currently dominating the market are The Cooper Companies Inc., Illumina Inc., Thermo Fisher Scientific Inc., PerkinElmer Inc., and Bioarray SL.